Eugenia Chock, MD, MPH
Assistant Professor of Medicine (Rheumatology, Allergy & immunology)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Titles
Assistant Professor of Medicine (Rheumatology, Allergy & immunology)
Biography
Dr. Chock is a physician and clinical researcher investigating medication use and offspring outcomes amongst parents with rheumatic diseases. She has strong interests in reproductive rheumatology and utilizing large datasets to support her research. Dr. Chock completed her MD degree at Dalhousie University in Nova Scotia, Canada. She completed her residency at New York Presbyterian in Queens, New York. Dr. Chock joined the Section of Rheumatology for her fellowship in 2016, she received her MPH degree from Johns Hopkins University.
Appointments
Rheumatology
Assistant ProfessorPrimary
Other Departments & Organizations
- Antiphospholipid Syndrome Program
- Internal Medicine
- Janeway Society
- Rheumatology
- Rheumatology, Allergy, & Immunology
- Yale Medicine
Education & Training
- Fellow
- Yale School of Medicine
- MPH
- Johns Hopkins University Bloomberg School of Public Health
- Resident
- New York Presbyterian (2013)
- MD
- Dalhousie University (2008)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Eugenia Chock's published research.
Publications Timeline
A big-picture view of Eugenia Chock's research output by year.
Emily Sirotich
Evelyn Hsieh, MD, PhD
Abhijeet Danve, MBBS, MD, MHS
Alexander B. Pine, MD, PhD
Alfred Lee, MD, PhD
Alyssa Ann Grimshaw, MBA, MLIS, MPH
9Publications
95Citations
Publications
2024
Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report.
Barbhaiya M, Taghavi M, Zuily S, Domingues V, Chock EY, Tektonidou MG, Erkan D, Seshan SV, New APS Classification Criteria Steering Committee and APS ACTION Collaborators. Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. J Rheumatol 2024, 51: 150-159. PMID: 37399462, DOI: 10.3899/jrheum.2022-1200.Peer-Reviewed Original Research
2023
Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Pine A, Butt A, Garcia-Milian R, Gu S, Restrepo V, Chock Y, Hwa J, Tormey C, Rinder H, Goshua G, Belmont H, Bertolaccini M, Branch D, Erhan D, Kello N, Knight J, Petri M, Willis R, Lee A, Sharda A. Proteomic Profiling of Different Antiphospholipid Antibody-Positive Phenotypes: Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry. Blood 2023, 142: 2575. DOI: 10.1182/blood-2023-185232.Peer-Reviewed Original ResearchConceptsNeutrophil extracellular trapsAntiphospholipid syndromeHumoral immune responseImmune responseClinical phenotypePathophysiology of APSPathogenesis of APSSapporo classification criteriaAPL-positive patientsPathway enrichment analysisEffector cell differentiationAntiPhospholipid Syndrome AllianceDifferent clinical phenotypesProteomic profilingPlasma proteomic profilingPatient plasma samplesAPL antibodiesAPS pathogenesisAntiphospholipid antibodiesObstetric complicationsPositive aPLCytokine stormMedian ageMicrovascular disordersConcurrent diagnosisOffspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review
Chock E, Dahal S, Grimshaw A, Suter L, Liew Z, Felson D. Offspring neurodevelopmental outcomes born to parents with chronic inflammatory arthritis using antirheumatic therapies: A scoping review. Seminars In Arthritis And Rheumatism 2023, 61: 152230. PMID: 37295300, PMCID: PMC10521166, DOI: 10.1016/j.semarthrit.2023.152230.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsChronic inflammatory arthritisOffspring neurodevelopmental outcomesAntirheumatic therapyNeurodevelopmental outcomesInflammatory arthritisTumor necrosis factor-alpha inhibitorsNecrosis factor-alpha inhibitorsNonsteroidal anti-inflammatory drugsEarly first trimesterOffspring health outcomesAnti-inflammatory drugsMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsWeb of ScienceAttention deficit hyperactive disorderCorticosteroid useRheumatic diseasesFirst trimesterCochrane LibraryAlpha inhibitorsStudy qualityMedication safetyFetal wellbeingIndependent reviewersMost women
2022
Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Domingues V, Chock EY, Dufrost V, Risse J, Seshan SV, Barbhaiya M, Sartelet H, Erkan D, Wahl D, Zuily S. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev 2022, 21: 103158. PMID: 35907609, DOI: 10.1016/j.autrev.2022.103158.Peer-Reviewed Original ResearchProlonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio M, Kennedy K, Liew JW, Putman MS, Sirotich E, Sattui SE, Foster G, Harrison C, Larché MJ, Levine M, Moni TT, Thabane L, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Gore-Massy M, Howard RA, Kodhek MA, Lalonde N, Tomasella LA, Wallace J, Akpabio A, Alpízar-Rodríguez D, Beesley RP, Berenbaum F, Bulina I, Chock EY, Conway R, Duarte-García A, Duff E, Gheita TA, Graef ER, Hsieh E, Kibbi L, Liew DF, Lo C, Nudel M, Singh AD, Singh JA, Singh N, Ugarte-Gil MF, Hausmann JS, Simard JF, Sparks JA. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2022, 8: e002587. PMID: 36104117, PMCID: PMC9475962, DOI: 10.1136/rmdopen-2022-002587.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSystemic autoimmune rheumatic diseasesCOVID-19 symptom durationSymptom durationAutoimmune rheumatic diseasesCOVID-19 onsetVaccines surveyRheumatic diseasesCOVID-19Test-confirmed COVID-19Complete symptom resolutionCOVID-19 severityCOVID-19 symptomsImmunomodulating medicationsComorbidity countSymptom resolutionBaseline characteristicsClinical characteristicsAcute symptomsVaccine dosesNovel viral variantsHigher oddsLower oddsDay 15Viral variantsLogistic regressionExperience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international survey
Chock EY, Putman M, Conway R, Danila MI, Hoyer B, Hsieh E, Jayatilleke A, Kilian A, Leipe J, Liew JW, Machado PM, Robinson PC, Singh N, Ung N, Yeoh SA, Wallace ZS, Grainger R, Cappelli LC. Experience with telemedicine among rheumatology clinicians during the COVID-19 pandemic: an international survey. Rheumatology Advances In Practice 2022, 6: rkac039. PMID: 35669677, PMCID: PMC9154733, DOI: 10.1093/rap/rkac039.Peer-Reviewed Original ResearchCitationsAltmetricConceptsRheumatology cliniciansHalf of cliniciansCoronavirus disease 2019 (COVID-19) pandemicYears age groupPerception of telemedicineSpecific clinical situationsQuality of careDisease 2019 pandemicCross-sectional online surveyInflammatory arthritisPhysical examinationTelemedicine encountersClinicians' perceptionsClinical scenariosClinical situationsAge groupsAdequate careFree-text responsesCliniciansCrystalline arthritisArthritisCOVID-19 pandemicTwo-thirdsTelemedicineAcademic affiliation
2021
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases
Hausmann J, Kennedy K, Simard J, Liew J, Sparks J, Moni T, Harrison C, Larché M, Levine M, Sattui S, Semalulu T, Foster G, Surangiwala S, Thabane L, Beesley R, Durrant K, Mateus E, Mingolla S, Nudel M, Palmerlee C, Richards D, Liew D, Hill C, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Sirotich E, Alliance C, Robinson P, Bhana S, Liew J, Sufka P, Singh N, Howard R, Kim A, Westrich-Robertson T, Sirotich E, Tsui E, Duarte-Garcia A, Sparks J, Tam H, Jayatilleke A, Konig M, Graef E, Putman M, Syed R, Korsten P, Mateus E, Sattui S, Wallace Z, Laura U, Adam K, Chock Y, White D, Zamora G, Traboco L, Patel A, Grainger R, Ugarte-Gil M, Gianfrancesco M, Amigues I, Sanchez-Alvarez C, Trupin L, Jacobsohn L, Beesley R, Hoyer B, Machado P, Makan K, Gossec L, Priyank C, Leipe J, Wallace B, Angeles-Han S, Almaghlouth I, Katherine W, Padula A, Berenbaum F, Treemarcki E, Sinha R, Lewandowski L, Webb K, Young K, Bulina I, Uribe S, Rubinstein T, Nolan M, Ang E, Venuturupalli S, Hausmann J, Dubreuil M, Pisoni C, Cosatti M, Campos J, Simard J, Conway R, Peterson T, Harrison C, Felix C, Richards D, Proulx L, Akpabio A, Worthing A, Laidlaw L, Reid P, Palmerlee C, Danila M, Sahar L, Linh N, Agarwal A, Studenic P, Liew D, Larche M, Mingolla S, Zamora E, Angevare S, Sinha R, Durrant K, Peirce A, Somers E, Cappelli L, Frankel B, Kumar B, Krupnikova S, Vega J, Frankovich J, Fernandez-Ruiz R, Velásquez M, Yeoh S, Marino M, Nudel M, Scott C, Rodríguez C, Mancheño A, Seo P, Gamboa-Cárdenas R, Pimentel-Quiroz V, Reátegui-Sokolova C, Kihara M, Lin C, Kattula D, Laila G, Carmona L, Wallace J, Yazdany J, Costello W, Gore-massy M, Tomasella L, Kodek M. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. The Lancet Rheumatology 2021, 3: e707-e714. PMID: 34316727, PMCID: PMC8298011, DOI: 10.1016/s2665-9913(21)00175-2.Peer-Reviewed Original ResearchConceptsRheumatic disease diagnosisRheumatic diseasesHealth care accessCOVID-19 diagnosisNon-inflammatory rheumatic diseasesSARS-CoV-2 exposureAdults age 18 yearsCOVID-19 pandemicRheumatic disease activityAutoimmune rheumatic diseasesSystemic lupus erythematosusHealth care useAge 18 yearsCOVID-19 exposurePatient experience surveysProtective behaviorsPublic health advicePatient support organisationsAntirheumatic medicationsMedication affordabilityDisease activityComplete responseLupus erythematosusRheumatoid arthritisSjögren's syndrome
2020
Corrigendum to “Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis” [AUTREV 18–11 (2019) 102395]
Chock Y, Moulinet T, Dufrost V, Erkan D, Wahl D, Zuily S. Corrigendum to “Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis” [AUTREV 18–11 (2019) 102395]. Autoimmunity Reviews 2020, 19: 102503. PMID: 32165134, DOI: 10.1016/j.autrev.2020.102503.Peer-Reviewed Original Research
2018
AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis
Chock Y, Danve A, School of Medicine O, Petri M, Fu W. AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis. Annals Of The Rheumatic Diseases 2018, 77: 1425. DOI: 10.1136/annrheumdis-2018-eular.4524.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusBody mass indexChronic kidney diseaseLow disease activityLupus nephritisSLE patientsDisease activityComplement levelsMass indexAvailable body mass indexBiopsy-proven lupus nephritisLow-grade inflammatory stateElevated body mass indexRetrospective cross-sectional studyFirst BMI measurementRisk of nephritisCategorical variablesHigher leptin levelsCross-sectional studyHigher complement levelsChi-square testLupus CohortCohort entryObese patientsACR criteria
Clinical Trials
Current Trials
Yale Rheumatology Program Patient Registry and Bio-Repository
HIC ID2000026608REGRoleSub InvestigatorPrimary Completion Date06/01/2030Recruiting ParticipantsGenderBothAge18 years - 99 yearsYale Lupus and Connective Tissue Disease Bio-Repository / Yale Rheumatology Bio-Repository
HIC ID1602017276REGRoleSub InvestigatorPrimary Completion Date06/30/2036Recruiting ParticipantsGenderBothAge18+ years
Clinical Care
Overview
Eugenia Chock, MD, MPH, is a physician and clinical researcher investigating medication use and offspring outcomes among parents with rheumatic diseases. She has strong interests in reproductive rheumatology and utilizing large datasets to support her research.
Dr. Chock completed her MD degree at Dalhousie University in Nova Scotia, Canada. She completed her residency at New York Presbyterian in Queens, New York. Dr. Chock joined the Section of Rheumatology for her fellowship in 2016; she received her MPH degree from Johns Hopkins University.
Clinical Specialties
Rheumatology
Fact Sheets
Lupus
Learn More on Yale MedicineDiagnosing Lupus Nephritis
Learn More on Yale MedicineThumb Arthritis
Learn More on Yale MedicineBursitis
Learn More on Yale Medicine
Board Certifications
Rheumatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2018
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
News
- September 10, 2024
Using AI to Detect Autoimmune Diseases in Women
- January 23, 2024
Investigating Maternal Inflammatory Arthritis and Pregnancy Outcomes
- August 15, 2022
Yale Rheumatology Joins National RISE Registry
- July 27, 2022
New Appointments & Promotions Within Department of Internal Medicine
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.